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Abstract 
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease with variable 
clinical presentation. SLE can affect all organs and the involvement of major organs can be life 
threatening. This study aimed to determine the relationship of Epidermal Growth Factor (EGF) and 
Cortisol hormone on SLE Disease. This study was carried out on (70) study sample, (36) were patients 
and (34) control. SLE disease had significant association between study groups and sex of patients with 
SEE disease were 16 times more likely to be female. There were significant mean differences of 
Epidermal growth factor and Cortisol Hormones by study groups. 
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Introduction 
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease 
with variable clinical presentation. SLE can affect all organs and the involvement of 
major organs can be life threatening. The exact pathological mechanisms of SLE remain 
elusive, and the etiology of SLE is known to be multifactorial [1]. 
No single clinical laboratory test is currently useful as an indicator of clinical 
disease activity. Attempts to establish markers have led to studies exploring titers of 
antibodies to double-stranded DNA (anti-ds DNA)[2] .Levels of complement, 
erythrocyte sedimentation rate(ESR), chemokine[3] and complement deposition on red 
blood cells[4]. One approach to identify markers of disease activity is to investigate 
expression levels of genes thought to be involved in the pathogenesis or manifestation  
of SLE. The variable expression of cytokines determined by these genes is thought to 
contribute to SLE itself, as well as to the heterogeneityof SLE[5]. Malarrash, 
discoidrash, photosensitivity, alopecia,oral,nasalulcers, polyarthralgia myalgia, 
polyarthritis, pleurisy/pericarditis and peritonitis, leukopenia, thrombocytopenia, 
hemolytic anemia, hematuria, proteinuria, azotemia, psychosis/seizures, peripheral/ 
cranial neuropathies are the classic features of disease. Other organ involvements are 
including cardiovascular, pulmonary, ophthalmic, gastrointestinal, and so on[6] . 
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The disease is much more prevalent in women than in men, especially in the 
fertile age[7]. The risk of flares after use of sex hormones as contraceptives or hormone-
replacement therapy, as well as in physiological conditions such as pregnancy and 
perperium is increased. Hypoandrogenism has been described in men with SLE, and 
androgen therapy is sometimes recommended for the treatment of some SLE 
manifestations[8] . 
 
Materials and Methods 
A hospital-based case-control study design was carried out on (36) patients with 
SLE disease and (34) control group seen at Rheumatology outpatient clinic in Merjan 
Teaching Hospital in Babylon - Iraq , have been collected between October 20 14- May 
2015,all patients and control were from the same ethnic group (Arabic). About three 
milliliters of venous blood were collected from each subject in the study. The blood 
was collected into gel tube and was separated by centrifugation at 3000 rpm for 15 mm. 
The remaining sera stored frozen at -20 °C until hormonal assayed. The EGF and 
cortisol hormone levels were estimated by ELISA test using Elabscience kit for EGF 
and for Accu-Bind IUSA kit cortisol. The statistical analysis performed using qi-square 
and independent t-test at (p  .05). 
 
Results 
1: Distribution of Study Groups by Socio-Demographic Characteristics 
The overall mean of age of patient and control groups were (29.08±10.63) and 
(30.20±11.36) years old, respectively. Table (1) shows the distribution of study groups 
by socio-demographic characteristics. There was significant association between study 
groups and sex of patients with SLE disease was 16 times more likely to be female, (p
  0.001). 
 
Table 1: Distribution of study groups by socio-demographic characteristics 
 
Variable Study group 
 
X2 P 
values 
Oddes Ratio 
(95% C.I.) 
Control No 
(%) 
SLE Patients 
No (%) 
Age group 
10-29 years** 
30-49 years 
50-69 years 
 
 
17 (50.0) 
15 (44.1) 
2(5.9) 
 
23 (63.9) 
12 (33.3) 
1(2.8) 
 
1.094 
0.618 
 
 
0.296 
0.432 
 
1.69(0.63-4.53) 
2.71(0.23-32.34) 
Sex 
Female 
Male 
 
16(47.1) 
18(52.9) 
 
33(91.7) 
3(8.3) 
16.569 <0.001* 12.37(3.17-48.23) 
Occupational 
status 
Employed 
Non-emjyed 
 
 
 
9(26.5) 
25(73.5) 
 
 
10(27.8) 
26(72.2) 
0.015 0.902 0.94(0.332.69) 
      
 
*(p .001), **reference group 
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2: Distribution of Study Groups by BMI 
The distribution of study groups by BMI. There was no significant association 
between study groups and BMI, (p  .05) as shows in table (2). 
 
Table 2: Distribution of study groups by BMI 
Variable Study group 
 
X2 P 
values 
Odes Ratio (95% 
C.I.) 
Control 
No (%) 
SLE 
Patients 
No (%) 
BMI 
Underweight <18.5 kg/rn2 
Normal weight 18.5-24.9 
kg/rn2 
Overweight 25-29.9kg/rn2 
Obese  3Oka/m2 
 
0(0.0) 
14(41.2) 
 
14(41.2) 
6(17.6) 
 
3(8.3) 
15(41.7) 
 
14(38.9) 
4(11.1) 
3.380 0.337 2.31(0.16-4.22) 
*(p .05), BMI: Body Mass Index 
 
The distribution of SLE patients by residence, (55.6%) of SLE patients was 
from rural areas and (60.6%) of control were from urban area (figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The distribution of SLE patients by consanguinity, (77.8%) of SLE patients 
were relatives and (40.6%) of control were non-relative (figure2). 
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Figure (2): distribution of SLE patients by consanguinity 
 
3: Distribution of SLE Patients by Medical History 
The overall mean duration of SEE was (5.60±4.41) years, (61.1%) of SEE patients 
suffered from the disease for less than five years duration. The overall mean BMI was 
(29.98±5.38) kg/rn2, (41.7%) of SEE patients have normal weight. (52.8%) of SLE 
patients were complained from flushing face and redness of different body parts (Table 
3). 
 
Table (3): Distribution of SLE Patients by Medical History 
 
Variable  Frequency (%) 
Duration of SLE 
< 5 years 
5 years 
Total 
 
22(61.1%) 
14(38.9%) 
36(100.0%) 
Signs and symptoms  
Flushing face and redness 
Edema 
Generalized pain  
Total 
 
19(52.8 %) 
10(27.8%) 
7(19.4%) 
36(100.0%) 
 
 
4: Distribution of SLE Patients by Response, Renal and CNS Involvement and 
ANA 
The Distribution of SLE Patients by Response, Renal and CNS Involvement 
and ANA. (58.3%), (58.3%), (63.9%) and (61.1%) of SLE patients have good response, 
no renal and CNS involvement and positive ANA, respectively table (4). 
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Table (4): Distribution of SLE Patients by Response, Renal and CNS 
Involvement and ANA 
Variable  Frequency(%) 
Response 
G 
P 
M 
Total 
 
21(58.3%) 
8(22.2%)  
7(19.5%) 
36(100.0%) 
Renal involvement 
Yes 
No 
Total 
 
 
15(41.7 %) 
21(58.3%) 
36(100.0%) 
CNS involvement 
Yes 
No 
Total 
 
13(36.1%) 
23(63.9%) 
36(100.0%) 
ANA 
Positive  
Negative  
Total  
 
 
22 (61.1%) 
14(38.9%) 
36 (100.0%) 
 
G: Good; P: Poor; M: Medium ; CNS: Central Nerves system; ANA: antinuclear 
antibodies 
 
5: Mean Differences of EGF and Cortisol by Study Groups 
The mean differences of EGF and cortisol by study groups. There was 
significant mean difference of EGF by study groups, (p   0.05) table (5). 
 
Table (5): Mean Differences of EGF and Cortisol by Study Groups 
Variable Study groups t-test P 
values SLE 
Mean ± SD 
Control 
Mean ± SD 
Epidermal growth factor 
(pg/ml) 
 
261.64 ± 
36.71 
198.48 ± 38.67 7.059 <0.001* 
Cortisol ( nmol / dL)  79.79± 20.40 90.74± 30.75 1.773 0.081 
 
 
6: Mean Differences of EGF and Cortisol by SLE Patients by Socio- Demographic 
Characteristics 
The mean differences of EGF and cortisol by SLE Patients by Socio 
Demographic Characteristics. There were no significant mean differences of EGF and 
cortisol SLE Patients by Socio-Demographic Characteristics,(p  .05) table (6): 
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Table (6): Mean Differences of EGF and Cortisol of SLE Patients by Socio 
Demographic Characteristics 
Variable Hormones 
EGF 
Mean ± SD 
Cortisol 
Mean ± SD 
Age group 
10-29 years  
30-49 years  
50-69 years 
ANOVE 
P value  
 
259.70±37.09 
267.23±38.05 
239.03±0.00 
0.348 
0.709 
 
77.18±15.65 
81.72±26.30 
116.72±0.0 
1.983 
0.154 
Sex 
Male  
Female  
t-test value  
P value 
 
256.41±29.56 
262.12±37.64 
0.254 
0.801 
 
76.17±6.74 
80.12±21.24 
0.317 
0.753 
Occupational status 
Employed   
Non-Employed  
t-test value  
P value 
 
243.41±31.56 
268.65±36.66 
1.918 
0.064 
 
75.89±31.56 
81.29±23.15 
0.706 
0.485 
Residence 
Urban area   
Rural area   
t-test value 
P value 
 
252.11±26.44 
269.27±42.34 
1.414 
0.164 
 
82.43±19.31 
77.68±21.48 
0.688 
0.496 
Marital status 
Married  
Single  
t-test value  
P value 
 
263.30±36.31 
260.81±37.65 
0.189 
0.851 
 
75.68±14.50 
81.85±22.79 
0.853 
0.400 
Consanguinity 
Yes  
No  
t-test value  
P value 
 
252.83±39.09 
257.48±28.63 
0.3 59 
0.722 
 
81.16±21.52 
74.99±16.13 
0.750 
0.458 
 
7: Mean Differences of EGF and Cortisol by SLE Patients by Medical History 
The mean differences of EGF and cortisol of SLE Patients by medical history. 
There was significant mean difference of cortisol by sign and symptoms, (p .05) table 
(7). 
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Table (7): Mean Differences of EGF and Cortisol of SLE Patients by Medical 
History 
 
Variable Hormones 
EGF 
Mean ± SD 
Cortisol 
Mean ± SD 
Duration of SLE  
<5 years  
 5yeam  
t-test value  
P value 
 
256.86±31.66 
269.15±43.70 
0.978 
0.335 
 
80.55±21.71 
78.59±18.88 
0.278 
0.783 
BMI 
Underweight < 18.5 kg/rn2   
Normal weight 18.5-24.9 kg/rn2  
Overweight 25.0-29.9 kg/rn2  
Obese :30kg/rn2  
ANOVA  
P value 
 
218.31±1634 
257.05±28.55 
260.29±23.83 
2.494 
0.078 
 
80.15±11.87 
78.26±23.11 
84.19±21.27 
0.538 
0.660 
 
Signs and symptoms 
Flushing face and redness  
Edema  
Generalized pain  
ANOVA  
p value  
 
259.14±3 1.92  
271.02±49.47 
255.04±30.26 
0.469 
0.630 
 
87.76±23.46 
71.03±11.39 
70.68±12.48 
3.510 
0.041* 
*(p  0.05) 
 
Discussion 
Systemic Lupus Erythematosus is a systemic disease characterized by 
immunologic abnormalities with pathologic changes mediated by tissue-binding 
autoantibodies and immune complexes. It affects a number of organs and systems and 
clinical manifestation are heterogeneous. Ninety percent of patients at diagnosis are 
women of childbearing years, people of all genders, ages, and ethnic groups are 
susceptible. Interaction between susceptibility genes and environmental factors and 
hormonal factors result in abnormal immune responses, which underlies the 
Pathogenesis of the disease by [9] 
In this study the total number of SLE patients was 36. 33 (91.7%) of patient was 
female and 3 (8.3%) was male, while the number of control group was 34 16 (47.1%) 
was female and 18 (52.9%) was male. 
Table (1) showed that there were significant differences between female and 
male (p < 0.001) in patient with SLE and the female to male ratio was 12.37. The result 
of this study agree with other studies that conducted by [10][11][12],[13],[14][15]that 
showed 90% of SLE patients was female . The reason for the high incident of SLE in 
female may be due to the role of estrogen and other gonadal hormones in the alteration 
of immune cell function and gene dose effect of the- X chromosome that is the presence 
of two X chromosomes in the female as opposed to the one X chromosome present in 
males .The X chromosome carries immunological related genes, which can mutate and 
contribute to the onset of SLE. As supported by the increased prevalence of SLE among 
men with Klinefilter syndrome. The Y chromosome has no identified mutations 
associated with autoimmune disease [16][14][15][18]  
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In this study the mean age group was (29.08±1063) for patient with SLE and 
(30.20±11.36) for control group. Table (1) showed the age group of SLE patients and 
control that was divided into three from 10-29 years was 23 (63.9%) , 30-49 years was 
12 (33.3%) and 50-69 years was 1 (2.8%) for the SLE patients , while the age of control 
group was 10-29 yearsnl7 (50.0%), 30-49 years was 15 (44.1%) and 50-69 years 2 
(5.9%).  
The results of the current study showed that the first group of age for SLE 
patients (10-29) years more than other groups other studies also showed the same of 
our results because this diseases affects women in 90% of the cases with a peak of 
incidence during childbearing years (15-44 years of age) thus suggesting that hormonal 
factors may trigger the disease onset and flares especially in pre-pubertal and post-
menopausal by [7][14][ [17][18] That suggest that the difference in the occurrence of 
SLE between female and male occurs between age 15 and 45, when women experience 
their highest exposure to estrogen, because the disease activity increases during 
pregnancy, a role for female hormones has been proposed. Lower levels of androgens, 
higher levels of estrogen and hyperprolactinemia beside this may be the male hormone, 
androgen, may have a protective function in lupus. 
The results of the current study showed that there were no significant 
association between study groups and occupational status , body mass index (13M1) 
and residence( p 0.05).The overall mean BMI was (29.98±5.38) kg/rn2, (41.7%) of SLE 
patients have normal weight, (8.3%) was underweight, and (38.9%) (11.1%) were 
overweight and obese respectively, obese respectively. The mean duration of SLE 
patients was (5.60±4.41) years (61.1%) of SLE patients suffered from the disease for 
less than five years, While 31% of patients more than five years. This agree with the 
study conducted by [19] 
The current study is concerned with SLE disease that dealing with hormonal, 
endocrine and genetic variation among patients with SEE. So in this thesis highlighted 
the hormones and its association and correlation with patients with SLE. The results 
that focus on epidermal growth factor (EGF) levels in SEE disease are controversial. 
The present study showed that the differences of EGF between patient and control. EGF 
level was increased significantly among patients with SLE compared to control (26 
1.64±36.71 and 198.48±36.67 pg/ml) respectively, especially in females which had 
higher levels than males, and both had higher levels compared to its level in the control 
group (262.12±37.64 and 256. 41±29.56 pg/mi). The EGF level was elevated along 
with the increasing duration of the disease, but it was insignificant (P  .05). This 
elevation in the hormone level may be due to part of body defense mechanism to reduce 
the tissue damage caused by SLE. Autoantibody. Responses to EGFR hold the potential 
of fulfilling a pathogenic role in autoimmune disease. [20] Differences in autoantibody 
effects on various cell types Thus, no firm conclusions can be made at this stage about 
the precise functional consequences of the autoantibodies in Sclerosis (S Sc) and SLE. 
Availability of homogeneous and renewable recombinant autoantibodies, however, can 
be anticipated to help delineate the role of the autoantibodies in future studies. Systemic 
Sclerosis is characterized by extensive fibrosis of skin and visceral organs. 
Also the present study agrees with study conducted by [21] the EGF level was 
significantly increased in patients with Behcet Disease in Iraqi population. Behcet’s 
disease is also autoimmune disease and a multi-systemic vascular disorder 
characterized by oral and genital  ulcers, as well as cutaneous, ocular, arthritic, vascular, 
central nervous system and gastrointestinal involvement. It usually affects young 
adults, and its pathological origin is unknown [22] 
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The SLE disease is a multi-systemic disorder. EGF elevation may be used as 
well in the treatment of patients with SLE that may be associated with sever symptoms 
and affecting vital organs such as eyes , CNS and Renal involvement .This hormone 
not used by itself in the treatment but can be used as a helper to control the damage in 
target organs . This kind of use known as bio-nanotechnology, which is a new 
interdisciplinary research area in cancer treatment amalgamating the disciplines of 
biology, physics, chemistry, engineering and medicine. 
Present study showed that there is a decrease of the value cortisol hormone level 
among patients with SLE in comparison to the control group (79.79± 20.40 90.74± 
30.75) respectively. This decrease of the hormone level was insignificant (p0.08 1) and 
this is also shown by the study conducted by [23] which found that in chronic 
inflammatory diseases, cortisol is reduced relative to the degree of systemic 
inflammation, as exemplified in African trypanosomiasis, Sjogrens syndrome, and 
(SLE). This is particularly the case when the disease persists over ,ong period of time 
(over weeks). This also agree with study conducted by [24] which found that the levels 
of cortisol hormone among patients with SLE was much lower than control group, low 
serum cortisol in chronic inflammatory disease are thought to be caused by increased 
renal excretion of steroid hormones, increased conversion or conjugation to 
downstream hormones such as cortisone or oestrogens and androstene and inadequate 
adrenal production or secretion of these hormones. This variation in the hormone levels 
may lead to autoimmunity because it had been suggested that autoimmune disease 
develop when endocrine changes caused by various stresses together with some 
regulatory defects affect autoreactive cell and exceed the critical threshold leading to 
autoimmunity by [25]This variation in the hormone levels may be attributed to ethnic 
and environmental factors. However, ethnic, genetic and environmental factors may be 
a major role in hormone variation. 
 
Conclusion 
 Hormonal assessment for patients with SLE disease of valuable information’s in 
patients can be helpful in determining the activity of the disease. 
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 ةخلاصال
الجسم المزمن مع اعراض سريريه متغيره ويمكن ان يؤثر على جميع اعضاء  ةالنظامي ةالذاتي ةمرض المناع ةالحمامي ةالذئب
ة وقد اجريت الدراس ةالحمامي ةوهرمون الكورتزول عند مرضى الذئب ةبين عامل نمو البشر ة الى تحديد العلاق ةهدفت الدراس .اةويهدد الحي
لعامل نمو  ةوجود فروقات ذات دلاله احصائي ةواثبت الدراس ةلون مجموعه السيطر شخصا يمث 43مريضا و 63ت عينه شمل 07على 
  ةوالكورتزول بين مجموعات الدراس ةالبش
  ة,العراق ,هرومون نمو البشر ةالحمامي ة:مرض داء الذئب دالةالكلمات ال
 
 
